Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles

A technology of syringoside and -PLGA, which is applied in the field of preparation of syringoside PLGA nanoparticles, can solve the problems of large oral dose of syringoside, affecting the effect of liver disease, poor compliance of patients taking medicine, etc. Good sealing rate and drug loading, and the effect of increasing bioavailability

Inactive Publication Date: 2013-10-23
李永吉
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the problem of syringpicroside in the treatment is that its oral dose is large, and the patient's medication compliance is poor.
After intravenous injection,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles
  • Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles
  • Preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1 First, in order to achieve the above object, the technical scheme adopted in the present invention is: first, take PLGA (LA:GA=50:50) and join in the mixed solution of dichloromethane and ethyl acetate 1:1, obtain Concentration is the PLGA solution of 15mg / ml, then syringin is dissolved in distilled water, makes the medicine solution of 8mg / ml; Secondly, according to the volume ratio of 1:3, medicine is added in the PLGA solution, ultrasonic emulsification, makes Colostrum, then, inject this colostrum into poloxamer at a mass concentration of 0.5% 188 The aqueous solution forms the primary double emulsion, and then the primary double emulsion is added to 0.5% poloxamer according to the volume of 1:6 times 188 After 1-2 hours of magnetic stirring at 800r / min, the mixed solution of dichloromethane and ethyl acetate was rotated under reduced pressure for 45-60min to volatilize to form a colloidal solution. After freeze-drying, syringin-PLGA Nanoparticles

Embodiment 2

[0023] Embodiment 2 First, in order to achieve the above object, the technical scheme adopted by the present invention is: first, take PLGA (LA:GA=50:50) and join in the mixed solution of dichloromethane and ethyl acetate 1:2, obtain Concentration is the PLGA solution of 20mg / ml, then syringin is dissolved in distilled water, makes the medicine solution of 10mg / ml; Secondly, according to the volume ratio of 1:11, medicine is added in the PLGA solution, ultrasonic emulsification, makes Colostrum, then, inject the colostrum to a mass concentration of 0.5% poloxamer 188 The aqueous solution forms the primary double emulsion, and then the primary double emulsion is added to 1% poloxamer according to the volume of 1:11 times 188 After 1-2 hours of magnetic stirring at 800r / min, the mixed solution of dichloromethane and ethyl acetate was rotated under reduced pressure for 45-60min to volatilize to form a colloidal solution. After freeze-drying, syringin-PLGA Nanoparticles

Embodiment 3

[0024] Embodiment 3 First, in order to achieve the above object, the technical scheme adopted by the present invention is: first, take PLGA (LA:GA=50:50) and join in the mixed solution of dichloromethane and ethyl acetate 1:3, obtain Concentration is the PLGA solution of 18mg / ml, then syringin is dissolved in distilled water, makes the medicine solution of 15mg / ml; Secondly, according to the volume ratio of 1:4, medicine is added in the PLGA solution, ultrasonic emulsification, makes Colostrum, then, inject this colostrum into poloxamer at a mass concentration of 0.5% 188 The aqueous solution forms the primary double emulsion, and then the primary double emulsion is added to 0.75% poloxamer according to the volume of 1:10 times 188 After 1-2 hours of magnetic stirring at 800r / min, the mixed solution of dichloromethane and ethyl acetate was rotated under reduced pressure for 45-60min to volatilize to form a colloidal solution. After freeze-drying, syringin-PLGA Nanoparticles ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation method of syringopicroside (SYR) poly(lactide-co-glycolide) (PLGA) nanoparticles. The preparation method comprises the following steps of: weighing SYR and dissolving SYR into distilled water to serve as an internal aqueous phase; weighing PLGA and dissolving PLGA into an organic solvent consisting of ethyl acetate and dichloromethane to serve as an organic phase; slowly adding the aqueous phase into the organic phase dropwise under magnetic stirring and performing ultrasonic treatment in ice-water bath to obtain SYR primary emulsion (W/O); injecting the prepared primary emulsion into an aqueous phase containing an emulsifier poloxamer188 and stirring to form SYR primary multiple emulsion; quickly injecting the multiple emulsion into an external aqueous phase solution comprising poloxamer188, rotationally evaporating the multiple emulsion at a certain temperature and under reduced pressure until the mixed solvent of the ethyl acetate and the dichloromethane is volatilized completely to obtain a nanoparticle colloidal solution; freeze-drying to obtain the SYR-PLGA nanoparticles. The SYR-PLGA nanoparticles prepared by the method can be used for improving the stability of the SYR, prolonging the drug action time, overcoming the defect of high metabolism velocity, most importantly, achieving targeted and slow-release effects, and improving the bioavailability.

Description

technical field [0001] The invention relates to a preparation method of medicine, in particular to a preparation method of syringpicroside PLGA nanoparticles. Background technique [0002] Hepatitis B is a worldwide, infectious disease caused by hepatitis B virus (HBV). Although hepatitis B vaccination has become an important means of prevention, millions of people are still infected with HBV every year. Looking for HBV There is an urgent need for specific drugs for the treatment of hepatitis. However, it is difficult for traditional hepatitis drugs to enter the liver cells and play a role, and the amount that can really enter the liver cells is not enough to inhibit HBV. How to combine anti-hepatitis B drugs with carriers and deliver them to the diseased liver, so that the carrier particles can be selectively concentrated in liver parenchymal cells, increase the concentration of drugs in the liver, and reduce the side effects of other organs. It has become one of the entr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/19A61K31/7048A61K47/34A61P1/16
Inventor 李永吉
Owner 李永吉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap